AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22233394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 0
Study 22233394 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study 20420544 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiates
Number of subjects: 0
Study 20420544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 20420544 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study 20420544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant medications (tricyclics and antiseizure)
Number of subjects: 0
Study 20420544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 17963628 — intervention group
Group type: EXPERIMENTAL
Intervention: EH + MS group
Number of subjects: 187
Study 17963628 — intervention group
Group type: COMPARATOR
Intervention: EH + nonMS group
Number of subjects: 187
Study 15910156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel bullying intervention
Number of subjects: 1023
Study 15910156 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1023
Study 11940063 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytohaemaglutinin (PHA) stimulation
Number of subjects: 0
Study 11940063 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM allergen stimulation
Number of subjects: 0
Study 11940063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 9893415 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 42
Study 9893415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 42
Study 9893415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7675045 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet with oats (50 to 70 g per day from three sources: two types of wheat-starch flour mixed with oats, muesli containing 60% oats, rolled-oat breakfast cereal)
Number of subjects: 92
Study 7675045 — intervention group
Group type: COMPARATOR
Intervention: Gluten-free diet without oats (control group)
Number of subjects: 92
Study 2301781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (atropine sulfate and isoetharine)
Number of subjects: 17
Study 2301781 — intervention group
Group type: COMPARATOR
Intervention: Isoetharine alone
Number of subjects: 17
Study 7008147 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam as pre-medication
Number of subjects: 204
Study 7008147 — intervention group
Group type: COMPARATOR
Intervention: No sedation (control group)
Number of subjects: 204
Study 31899882 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal laser interstitial thermotherapy (SLITT)
Number of subjects: 80
Study 31899882 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 80
Study 31899882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SLITT and open surgery
Number of subjects: 80
Study 30681185 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone (150 mg/day)
Number of subjects: 369
Study 30681185 — intervention group
Group type: COMPARATOR
Intervention: NSAID only (Control)
Number of subjects: 369
Study 30681185 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone (150 mg/day) with long-term low-dose aspirin
Number of subjects: 369
Study 30681185 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone (150 mg/day) with other NSAIDs
Number of subjects: 369
Study 27981861 — intervention group
Group type: EXPERIMENTAL
Intervention: CE group
Number of subjects: 40
Study 27981861 — intervention group
Group type: COMPARATOR
Intervention: CM group
Number of subjects: 40
Study 24798789 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 13
Study 24798789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 22452898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction (SI)
Number of subjects: 83
Study 21067829 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0677 (25mg/day)
Number of subjects: 123
Study 21067829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 19034732 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg)
Number of subjects: 32
Study 19034732 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) (40 mg)
Number of subjects: 32
Study 19034732 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 32
Study 16098428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with hirudin/PPACK
Number of subjects: 36
Study 16098428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with citrate
Number of subjects: 36
Study 16098428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16098428 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 36
Study 16098428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 36
Study 11922255 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% autogenous bone plus 50% demineralized freeze-dried bone allograft (DFDBA group)
Number of subjects: 10
Study 11922255 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% autogenous bone plus 50% hydroxyapatite (HA group)
Number of subjects: 10
Study 10597880 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA (2.5 mg/day)
Number of subjects: 9
Study 10597880 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + NG (0.05 mg/day)
Number of subjects: 9
Study 10597880 — intervention group
Group type: COMPARATOR
Intervention: CEE only (control)
Number of subjects: 9
Study 8565031 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin salmon nasal spray (200 IU/d)
Number of subjects: 81
Study 8565031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8565031 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin salmon nasal spray
Number of subjects: 81
Study 2035326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline (n = 11)
Number of subjects: 22
Study 2035326 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 11)
Number of subjects: 22
Study 7180926 — intervention group
Group type: EXPERIMENTAL
Intervention: CABCURVE cellulose acetate buterate (CAB) contact lenses
Number of subjects: 10
Study 7180926 — intervention group
Group type: COMPARATOR
Intervention: Polymethyl methacrylate (PMMA) lenses
Number of subjects: 10
Study 7180926 — intervention group
Group type: COMPARATOR
Intervention: Polycon lenses
Number of subjects: 10
Study 31760586 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP via a facemask delivering 100% supplemental oxygen
Number of subjects: 185
Study 31760586 — intervention group
Group type: COMPARATOR
Intervention: Standard O2 via nasal cannula or non-rebreather mask (control group)
Number of subjects: 185
Study 31760586 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP via a tight‐fitting mask
Number of subjects: 185
Study 30675706 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT)
Number of subjects: 0
Study 28485777 — intervention group
Group type: EXPERIMENTAL
Intervention: cisatracurium besylate combined with propofol and fentanyl
Number of subjects: 120
Study 28485777 — intervention group
Group type: COMPARATOR
Intervention: 0.10 mg/kg vecuronium bromide combined with propofol and fentanyl
Number of subjects: 120
Study 26276457 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation phase (therapist held the needle)
Number of subjects: 30
Study 26276457 — intervention group
Group type: COMPARATOR
Intervention: Control phase (needle untouched)
Number of subjects: 30
Study 23400347 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-rated DSM-IV referenced anxiety scale
Number of subjects: 415
Study 21052737 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq(®) laryngoscope with a fiberoptic bronchoscope (FOB)
Number of subjects: 8
Study 21052737 — intervention group
Group type: COMPARATOR
Intervention: Airtraq(®) alone
Number of subjects: 8
Study 18991973 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Stress Index (PSI)
Number of subjects: 80
Study 18991973 — intervention group
Group type: EXPERIMENTAL
Intervention: Family functioning measures (family support, family cohesion and adaptability, coping strategies, family needs, locus of control)
Number of subjects: 80
Study 18991973 — intervention group
Group type: EXPERIMENTAL
Intervention: Griffiths Scales and Gross Motor Function measure
Number of subjects: 80
Study 18991973 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Observation for Measuring the Environment
Number of subjects: 80
Study 17304174 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (ON condition)
Number of subjects: 20
Study 17304174 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (OFF condition)
Number of subjects: 20
Study 16166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 microg)
Number of subjects: 17
Study 16166613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16166613 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 17
Study 12063951 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms/8 h)
Number of subjects: 30
Study 12063951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12063951 — intervention group
Group type: COMPARATOR
Intervention: Octreotide and Placebo
Number of subjects: 30
Study 10615236 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling group led by professional psychologists (PG)
Number of subjects: 0
Study 10615236 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling group led by former smokers (SG)
Number of subjects: 0
Study 10615236 — intervention group
Group type: COMPARATOR
Intervention: No intervention group (NG)
Number of subjects: 0
Study 10615236 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent subjects
Number of subjects: 0
Study 7813328 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 7813328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 0
Study 7813328 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin followed by oral anticoagulants
Number of subjects: 0
Study 1958248 — intervention group
Group type: EXPERIMENTAL
Intervention: Visited and shown a leaflet and fact sheet (219)
Number of subjects: 737
Study 1958248 — intervention group
Group type: EXPERIMENTAL
Intervention: Visited and shown a video (263)
Number of subjects: 737
Study 1958248 — intervention group
Group type: EXPERIMENTAL
Intervention: Posted a leaflet and fact sheet (131)
Number of subjects: 737
Study 1958248 — intervention group
Group type: COMPARATOR
Intervention: Not contacted at all (124)
Number of subjects: 737
Study 7308554 — intervention group
Group type: EXPERIMENTAL
Intervention: Betnovate (betamethasone 17‐valerate, 0.1%) cream diluted to 50% in various vehicles
Number of subjects: 0
Study 7308554 — intervention group
Group type: EXPERIMENTAL
Intervention: E45 dilution of betamethasone 17‐valerate
Number of subjects: 0
Study 7308554 — intervention group
Group type: EXPERIMENTAL
Intervention: Other formulations tested
Number of subjects: 0
Study 30557295 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Number of subjects: 0
Study 30557295 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient physical therapy (PT)
Number of subjects: 0
Study 28209333 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (0.9 g GTE per day for 12 months)
Number of subjects: 176
Study 28209333 — intervention group
Group type: COMPARATOR
Intervention: Control group without GTE supplementation
Number of subjects: 176
Study 26892863 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 1903
Study 26892863 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 1903
Study 26892863 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF and E/C/F/TDF
Number of subjects: 1903
Study 24154935 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg once-daily
Number of subjects: 16
Study 24154935 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 2.5mg twice-daily
Number of subjects: 16
Study 21824990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg titrated to 300 mg once daily after 3 months)
Number of subjects: 599
Study 21824990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study 21824990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 599
Study 19838721 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt expansion of the uterine incision
Number of subjects: 200
Study 19838721 — intervention group
Group type: COMPARATOR
Intervention: Sharp expansion of the uterine incision
Number of subjects: 200
Study 17236920 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous mandibular angle resection and bilateral sagittal split ramus osteotomy (BSSRO)
Number of subjects: 26
Study 17236920 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sagittal split ramus osteotomy (BSSRO) only (Control)
Number of subjects: 26
Study 14676992 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (50 microg transdermal 17beta‐estradiol)
Number of subjects: 32
Study 14676992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12431265 — intervention group
Group type: EXPERIMENTAL
Intervention: Home support from nurses who were certified lactation consultants
Number of subjects: 138
Study 12431265 — intervention group
Group type: COMPARATOR
Intervention: Standard care and standard length of hospitalization
Number of subjects: 138
Study 9660986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cimetidine
Number of subjects: 12
Study 9660986 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin alone
Number of subjects: 12
Study 7661232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 7661232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2706727 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil plus sulfisoxazole
Number of subjects: 380
Study 2706727 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil alone
Number of subjects: 380
Study 2706727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole
Number of subjects: 380
Study 2706727 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamins)
Number of subjects: 380
Study 1251156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactrim (2 x 2 tablets or ampoules daily)
Number of subjects: 143
Study 1251156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (parenterally and orally)
Number of subjects: 143
Study 31691123 — intervention group
Group type: EXPERIMENTAL
Intervention: T1‐mVISTA
Number of subjects: 30
Study 31691123 — intervention group
Group type: COMPARATOR
Intervention: T1‐MP‐RAGE
Number of subjects: 30
Study 30354371 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS-CP application
Number of subjects: 871
Study 26589819 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (n = 9048)
Number of subjects: 42418
Study 26589819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (n = 9,054)
Number of subjects: 42418
Study 26589819 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (n = 15,255)
Number of subjects: 42418
Study 26589819 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine vs Chlorthalidone
Number of subjects: 42418
Study 26589819 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril vs Chlorthalidone
Number of subjects: 42418
Study 24388839 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days, followed by tablet every 2 days
Number of subjects: 95
Study 24388839 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet every 2 days
Number of subjects: 95
Study 22868974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (four sessions, progressive reduction of smoking)
Number of subjects: 92
Study 22868974 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (single session, immediate cessation of smoking)
Number of subjects: 92
Study 22868974 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 92
Study 20406615 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 201
Study 20406615 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microg daily)
Number of subjects: 201
Study 20406615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoid dose
Number of subjects: 201
Study 20406615 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pre-existing fractures
Number of subjects: 201
Study 18566487 — intervention group
Group type: EXPERIMENTAL
Intervention: Paling Perspective Scale
Number of subjects: 400
Study 18566487 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group
Number of subjects: 400
Study 18566487 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 400
Study 18566487 — intervention group
Group type: COMPARATOR
Intervention: Numerical presentation of risk comparisons
Number of subjects: 400
Study 16053211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological stabilization
Number of subjects: 94
Study 16053211 — intervention group
Group type: COMPARATOR
Intervention: Mechanical stabilization (PCI)
Number of subjects: 94
Study 12578765 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of the ICL
Number of subjects: 291
Study 10333345 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 20% infusion at 0.3, 1.0, and 3.0 ml/min for 5 min each
Number of subjects: 8
Study 10333345 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% infusion
Number of subjects: 8
Study 10333345 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 20% infusion during local hyperinsulinaemia (insulin 0.05 mU/kg/min)
Number of subjects: 8
Study 10333345 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% infusion during local hyperinsulinaemia
Number of subjects: 8
Study 8983282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin dose adjustment to reach a target plasma concentration of total platinum (TP) of 2000 mu/l
Number of subjects: 27
Study 8983282 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin without dose adjustment
Number of subjects: 27
Study 8983282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin dose adjustment
Number of subjects: 27
Study 8983282 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (AUC)
Number of subjects: 27
Study 1834864 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide (250 mg 3 times daily)
Number of subjects: 571
Study 1834864 — intervention group
Group type: COMPARATOR
Intervention: Goserelin acetate alone
Number of subjects: 571
Study 1834864 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide
Number of subjects: 571
Study 6161670 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucomethylene blue staining
Number of subjects: 60
Study 6161670 — intervention group
Group type: COMPARATOR
Intervention: Control (no staining)
Number of subjects: 60
Study 30580081 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (450–900 mg)
Number of subjects: 46
Study 29266752 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gas aspiration via a subdiaphragmatic port
Number of subjects: 142
Study 29266752 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive-valve release via a subdiaphragmatic port valve opening
Number of subjects: 142
Study 29266752 — intervention group
Group type: COMPARATOR
Intervention: Gas release from the surgical wound without port release (Control group)
Number of subjects: 142
Study 26791438 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment twice a week for 2 months
Number of subjects: 30
Study 26791438 — intervention group
Group type: COMPARATOR
Intervention: Varicocelectomy
Number of subjects: 30
Study 26791438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 25247967 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-slice low-dose CT measurements in airways with a luminal diameter of 5 to 10 mm
Number of subjects: 100
Study 25247967 — intervention group
Group type: COMPARATOR
Intervention: Thin-slice low-dose CT measurements in airways with a luminal diameter of 10 mm or greater
Number of subjects: 100
Study 23060038 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO
Number of subjects: 209
Study 23060038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 20075648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagoclone
Number of subjects: 132
Study 20075648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 20075648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagoclone (open-label extension)
Number of subjects: 132
Study 18573585 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 PUFAs 1.8 g/day
Number of subjects: 46
Study 18573585 — intervention group
Group type: COMPARATOR
Intervention: placebo (olive oil)
Number of subjects: 46
Study 15580457 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI)
Number of subjects: 52
Study 15580457 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Related Quality of Life (VRQOL)
Number of subjects: 52
Study 15580457 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without voice complaints)
Number of subjects: 52
Study 12549684 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 75
Study 12549684 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 75
Study 12549684 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 75
Study 10863061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (S + R)
Number of subjects: 366
Study 10863061 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (S alone)
Number of subjects: 366